<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03229291</url>
  </required_header>
  <id_info>
    <org_study_id>SM04755-TOP-01</org_study_id>
    <nct_id>NCT03229291</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of SM04755 Following Topical Administration to Healthy Subjects</brief_title>
  <official_title>A Phase 1, Single-Center, Randomized, Single-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of SM04755 Following Topical Administration to Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biosplice Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biosplice Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a single-center, randomized, single-blind, placebo-controlled, multiple&#xD;
      ascending dose study of SM04755 solution applied topically once daily for 14 days to intact&#xD;
      skin overlying the inner thigh of healthy subjects at an estimated body surface area (BSA) of&#xD;
      80 cm^2. Dosing cohorts will consist of 8 subjects who will be randomized 3:1&#xD;
      (SM04755:placebo).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 3, 2016</start_date>
  <completion_date type="Actual">June 11, 2017</completion_date>
  <primary_completion_date type="Actual">June 11, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events (AEs)</measure>
    <time_frame>Day 28</time_frame>
    <description>Incidence and severity of AEs events during the treatment and observation periods of the study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinical laboratory abnormalities</measure>
    <time_frame>Day 28</time_frame>
    <description>Incidence and severity of clinical laboratory measurements that are outside the normal range</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in vital signs: blood pressure</measure>
    <time_frame>Baseline and Day 28</time_frame>
    <description>Change from baseline in blood pressure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in vital signs: temperature</measure>
    <time_frame>Baseline and Day 28</time_frame>
    <description>Change from baseline in temperature</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in vital signs: respiratory rate</measure>
    <time_frame>Baseline and Day 28</time_frame>
    <description>Change from baseline in respiratory rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in vital signs: pulse rate</measure>
    <time_frame>Baseline and Day 28</time_frame>
    <description>Change from baseline in pulse rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in electrocardiogram (ECG) parameters</measure>
    <time_frame>Baseline and Day 28</time_frame>
    <description>Change from baseline in 12-lead ECG parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma pharmacokinetics (PK): Cmax</measure>
    <time_frame>Day 1</time_frame>
    <description>Maximum plasma concentration (Cmax) estimate for SM04755 following first dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma pharmacokinetics (PK):tmax</measure>
    <time_frame>Day 1</time_frame>
    <description>Time to Cmax estimate for SM04755 following first dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma pharmacokinetics (PK): AUC</measure>
    <time_frame>Day 1</time_frame>
    <description>Area under the plasma concentration-time curve (AUC) estimate for SM04755 following first dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma pharmacokinetics (PK):half-life</measure>
    <time_frame>Day 1</time_frame>
    <description>Plasma terminal phase half-life estimate for SM04755 following first dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma pharmacokinetics (PK):Cmax</measure>
    <time_frame>Day 14</time_frame>
    <description>Maximum plasma concentration (Cmax) estimate for SM04755 following last dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma pharmacokinetics (PK):tmax</measure>
    <time_frame>Day 14</time_frame>
    <description>Time to Cmax estimate for SM04755 following last dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma pharmacokinetics (PK): AUC</measure>
    <time_frame>Day 14</time_frame>
    <description>AUC estimate for SM04755 following last dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma pharmacokinetics (PK):half-life</measure>
    <time_frame>Day 14</time_frame>
    <description>Plasma terminal phase half-life estimate for SM04755 following last dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in skin score assessment: erythema</measure>
    <time_frame>Baseline and Day 28</time_frame>
    <description>Change from baseline in erythema skin score assessment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in skin score assessment: scaling</measure>
    <time_frame>Baseline and Day 28</time_frame>
    <description>Change from baseline in scaling skin score assessment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in skin score assessment: pruritus/itching</measure>
    <time_frame>Baseline and Day 28</time_frame>
    <description>Change from baseline in pruritus/itching skin score assessment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in skin score assessment: burning/stinging</measure>
    <time_frame>Baseline and Day 28</time_frame>
    <description>Change from baseline in burning/stinging skin score assessment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of AEs relative to exposure</measure>
    <time_frame>Day 28</time_frame>
    <description>Incidence and severity of AEs relative to measured plasma exposure to SM04755</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Tendinopathy</condition>
  <arm_group>
    <arm_group_label>Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical SM04755 solution (15 mg/mL) applied once per day for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mid Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical SM04755 solution (45 mg/mL) applied once per day for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical SM04755 solution (90 mg/mL) applied once per day for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle solution applied once per day for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SM04755</intervention_name>
    <description>SM04755 is a small molecule inhibitor of the Wnt pathway.</description>
    <arm_group_label>High Dose</arm_group_label>
    <arm_group_label>Low Dose</arm_group_label>
    <arm_group_label>Mid Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>Same formulation as topical SM04755 solution, without SM04755 included.</description>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body mass index of 18 to 30 kg/m^2 at study start&#xD;
&#xD;
          -  Subject must have read and understood the informed consent form, and must have signed&#xD;
             it prior to any study-related procedure being performed&#xD;
&#xD;
          -  Willingness to comply with all scheduled study visits, laboratory tests, contraception&#xD;
             requirements and other study procedures&#xD;
&#xD;
          -  Appropriate skin characteristics at site of application (inner thigh) (for example,&#xD;
             consistent pigmentation, no tattoos, no scarring or noted injury, no varicose veins or&#xD;
             structural repair)&#xD;
&#xD;
          -  Willing to avoid extensive sun exposure, phototherapy, or use of a tanning salon for&#xD;
             the duration of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women who are pregnant or lactating&#xD;
&#xD;
          -  Women of childbearing potential who are sexually active and are not willing to use a&#xD;
             highly effective method of birth control during the study period that includes double&#xD;
             barrier, intrauterine device (IUD), or hormonal contraceptive combined with single&#xD;
             barrier, or abstinence&#xD;
&#xD;
          -  Males who are sexually active and not willing to use a condom, and have a partner who&#xD;
             is capable of becoming pregnant, if neither has had surgery to become sterilized,&#xD;
             and/or who are not willing to use double barrier or whose partner is not using a&#xD;
             highly effective method of birth control (e.g., IUD or hormonal contraception combined&#xD;
             with single barrier).&#xD;
&#xD;
          -  History of, or current, skin disease (for example, psoriasis, atopic dermatitis,&#xD;
             seborrheic dermatitis, and skin cancer)&#xD;
&#xD;
          -  History of, or current, skin damage at the treatment site (inner thigh) (for example,&#xD;
             cuts, abrasion, sunburn, sun-damage, or scarring)&#xD;
&#xD;
          -  Phototherapy or use of a tanning salon 2 weeks prior to study start until end of the&#xD;
             study (Day 28)&#xD;
&#xD;
          -  History of, or current, allergy to investigational product/placebo ingredients&#xD;
&#xD;
          -  Known allergy to adhesive tape&#xD;
&#xD;
          -  Current evidence of malignancy or history of malignancy within the last 5 years prior&#xD;
             to study start; prior history of in situ cancer or basal or squamous cell skin cancer,&#xD;
             completely excised, is allowed&#xD;
&#xD;
          -  Treatment with an investigational product within 12 weeks prior to study start; the&#xD;
             last date of participation in the trial, not the last date of receipt of&#xD;
             investigational product, must be at least 12 weeks prior to study start&#xD;
&#xD;
          -  Use of any prescription or nonprescription drugs [except birth control or hormone&#xD;
             replacement therapy (HRT)], topical skin treatments on the application site (inner&#xD;
             thigh), vitamins, grapefruit/grapefruit juice, or dietary or herbal supplements within&#xD;
             14 days prior to study start&#xD;
&#xD;
          -  Blood donation of ≥ 1 pint (473 mL) within 56 days prior to study start or unwilling&#xD;
             to refrain from blood donation for the duration of the study&#xD;
&#xD;
          -  Plasma or platelet donation within 14 days prior to study start or unwilling to&#xD;
             refrain from plasma or platelet donation for the duration of the study&#xD;
&#xD;
          -  Unwilling to refrain from sperm donation for the duration of the study and until 90&#xD;
             days after dose administration&#xD;
&#xD;
          -  Prior or current latent or active tuberculosis (TB) or nontuberculous mycobacteria&#xD;
             infection.&#xD;
&#xD;
          -  Evidence of active infection or illness involving fever within 7 days prior to study&#xD;
             start&#xD;
&#xD;
          -  Occurrence of serious illness requiring hospitalization within 6 months prior to study&#xD;
             start&#xD;
&#xD;
          -  Regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for&#xD;
             men (1 drink = 5 ounces [150 mL] of wine or 12 ounces [360 mL] of beer or 1.5 ounces&#xD;
             [45 mL] of hard liquor) within 6 months prior to study start&#xD;
&#xD;
          -  Use of tobacco- or nicotine-containing products (cigarettes, pipe, cigar, chewing&#xD;
             tobacco or nicotine gum, lozenges or patches) within 30 days prior to study start&#xD;
&#xD;
          -  A history of abuse of prescription or illicit drugs within 6 months prior to study&#xD;
             start&#xD;
&#xD;
          -  Marijuana use within 28 days prior to study start&#xD;
&#xD;
          -  Previous treatment with SM04755&#xD;
&#xD;
          -  Subjects who have a current or pending disability claim, workers' compensation, or&#xD;
             litigation(s) that may compromise response to treatment&#xD;
&#xD;
          -  Subjects who are immediate family members (spouse, parent, child, or sibling;&#xD;
             biological or legally adopted) of personnel directly affiliated with the study at the&#xD;
             investigative site, or are directly affiliated with the study at the investigative&#xD;
             site&#xD;
&#xD;
          -  Subjects employed by Samumed, LLC, or any of its affiliates or development partners&#xD;
             (that is, an employee, temporary contract worker, or designee) responsible for the&#xD;
             conduct of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yusuf Yazici, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Biosplice Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>July 18, 2017</study_first_submitted>
  <study_first_submitted_qc>July 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 25, 2017</study_first_posted>
  <last_update_submitted>July 21, 2017</last_update_submitted>
  <last_update_submitted_qc>July 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SM04755</keyword>
  <keyword>topical</keyword>
  <keyword>Samumed</keyword>
  <keyword>Wnt inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tendinopathy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

